Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 06, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on January 05, 2006:
- Previous Holdings: 18,475,715 Ordinary Share ADRs
- New Holdings: 18,447,919 Ordinary Share ADRs
- Net Change: Decrease of 27,796 ADRs
- Average Price: $50.48 per ADR
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the reported transaction.
Key Facts for Investor Verification
- Verify the impact of the 27,796 ADR reduction on the total beneficial ownership of the US Retirement Savings Plan.
- Confirm the specific nature of the "fund movement" that triggered the change in share count.
- Review the broader context of Dr. J P Garnier and Dr. T Yamada's total holdings to assess the significance of their indirect interest in this specific fund.